{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:05:21Z","timestamp":1790877921193,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xkme.2026.101476","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:29:13Z","timestamp":1784302153000},"page":"101476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-6259","authenticated-orcid":false,"given":"Suman","family":"Lama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Nandorine","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Usvyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Hippen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2026.101476_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.ajkd.2024.08.002","article-title":"Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT trials","volume":"85","author":"Taal","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2026.101476_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.xkme.2026.101476_bib3","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.xkme.2026.101476_bib4","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.2215\/CJN.00710111","article-title":"C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients","volume":"6","author":"Bazeley","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101476_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/hdi.12407","article-title":"The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure","volume":"20","author":"Chait","year":"2016","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101476_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101476_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.xkme.2026.101476_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101476_bib9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of Inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xkme.2026.101476_bib10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ndt\/gfn543","article-title":"Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients","volume":"24","author":"Bradbury","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2026.101476_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1681\/ASN.2020050595","article-title":"Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.xkme.2026.101476_bib12","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.xkme.2026.101476_bib15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101476_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000437005","article-title":"Relationship of neutrophil-to-lymphocyte ratio and serum albumin levels with C-reactive protein in hemodialysis patients: results from 2 international cohort studies","volume":"130","author":"Malhotra","year":"2015","journal-title":"Nephron"},{"issue":"8","key":"10.1016\/j.xkme.2026.101476_bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1159\/000519644","article-title":"Neutrophil-to-lymphocyte ratio and erythropoietin resistance among maintenance hemodialysis patients","volume":"51","author":"Zhang","year":"2022","journal-title":"Blood Purif"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:09Z","timestamp":1790875989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2590059526002384"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101476","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101476"}}